Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Permethrin pediculicides possible ineffectiveness to be investigated by FDA working group.

This article was originally published in The Tan Sheet

Executive Summary

PERMETHRIN PEDICULICIDES POSSIBLE INEFFECTIVENESS TO BE EXAMINED BY FDA working group, according to an Aug. 20 letter by Center for Drug Evaluation & Research Director Janet Woodcock, MD. Responding to an inquiry from Virginia Attorney General Richard Cullen, Woodcock said FDA is "aware of reports alleging ineffective treatment of head lice with OTC permethrin-containing drug products" and is "organizing a cross-agency working group to investigate the reports, identify the problems and develop a plan of action to address them." Permethrin is the active ingredient in Warner-Lambert's Nix, the leading OTC pediculicide.
Advertisement

Related Content

Pyrethrum Pediculicide Labeling Revisions Would Provide More Detail – FDA
Pyrethrum Pediculicide Labeling Revisions Would Provide More Detail – FDA
Pyrethrum Pediculicide Labeling Revisions Would Provide More Detail – FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS087537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel